$MHTX
MANHATTAN SCIENTIFICS INC

2024 Q3 Form 10-Q Financial Statement

#000147793224005089 Filed on August 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $158.0K
YoY Change -12.71%
% of Gross Profit
Research & Development $2.000K
YoY Change -60.0%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $160.0K
YoY Change -13.98%
Operating Profit -$160.0K
YoY Change -13.98%
Interest Expense $2.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.000K
YoY Change -104.65%
Pretax Income -$158.0K
YoY Change -31.0%
Income Tax
% Of Pretax Income
Net Earnings -$158.0K
YoY Change -31.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 559.3M shares 559.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.00K
YoY Change -26.92%
Cash & Equivalents $38.00K
Short-Term Investments
Other Short-Term Assets $7.000K
YoY Change -22.22%
Inventory
Prepaid Expenses $7.000K
Receivables
Other Receivables
Total Short-Term Assets $45.00K
YoY Change -26.23%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $27.00K
YoY Change -94.66%
Other Assets $2.000K
YoY Change 0.0%
Total Long-Term Assets $29.00K
YoY Change -94.29%
TOTAL ASSETS
Total Short-Term Assets $45.00K
Total Long-Term Assets $29.00K
Total Assets $74.00K
YoY Change -86.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $156.0K
YoY Change 24.8%
Accrued Expenses $2.180M
YoY Change 32.12%
Deferred Revenue
YoY Change
Short-Term Debt $60.00K
YoY Change -14.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.416M
YoY Change 30.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.416M
Total Long-Term Liabilities $0.00
Total Liabilities $2.416M
YoY Change 30.24%
SHAREHOLDERS EQUITY
Retained Earnings -$72.96M
YoY Change 1.47%
Common Stock $559.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.400M
YoY Change
Total Liabilities & Shareholders Equity $74.00K
YoY Change -86.99%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$158.0K
YoY Change -31.0%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$17.00K
YoY Change -73.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.000K
YoY Change -84.62%
Cash From Investing Activities $4.000K
YoY Change -84.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -17.00K
Cash From Investing Activities 4.000K
Cash From Financing Activities 0.000
Net Change In Cash -13.00K
YoY Change -65.79%
FREE CASH FLOW
Cash From Operating Activities -$17.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</p>
dei Entity Central Index Key
EntityCentralIndexKey
0001099132
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
MANHATTAN SCIENTIFICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
000-28411
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0460639
dei Entity Address Address Line1
EntityAddressAddressLine1
244 Fifth Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2341
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
541-2405
dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
559281064 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67000 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
45000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
69000 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
27000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
245000 usd
CY2024Q2 us-gaap Other Assets
OtherAssets
2000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
2000 usd
CY2024Q2 us-gaap Assets
Assets
74000 usd
CY2023Q4 us-gaap Assets
Assets
316000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
156000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
133000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2180000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1915000 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10000 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
60000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
60000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2416000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2118000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
2416000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2118000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1058000 usd
CY2023Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1058000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
559000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
559000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
68996000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
68996000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72955000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72415000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3400000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2860000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
74000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
316000 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
158000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
181000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
347000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
367000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
160000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
186000 usd
us-gaap Operating Expenses
OperatingExpenses
352000 usd
us-gaap Operating Expenses
OperatingExpenses
372000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-160000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-186000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-352000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-372000 usd
CY2024Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
2000 usd
CY2023Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-43000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-188000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-292000 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-188000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-277000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-158000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-229000 usd
us-gaap Net Income Loss
NetIncomeLoss
-540000 usd
us-gaap Net Income Loss
NetIncomeLoss
-649000 usd
CY2024Q2 mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
CY2023Q2 mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
CY2024Q2 mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
CY2023Q2 mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2860000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-382000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3242000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-158000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3400000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1695000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-420000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2115000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-229000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2344000 usd
us-gaap Profit Loss
ProfitLoss
540000 usd
us-gaap Profit Loss
ProfitLoss
649000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000 usd
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
188000 usd
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
292000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
23000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
265000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
211000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-139000 usd
mhtx Proceeds From Sale Of Assets Held For Sale
ProceedsFromSaleOfAssetsHeldForSale
0 usd
mhtx Proceeds From Sale Of Assets Held For Sale
ProceedsFromSaleOfAssetsHeldForSale
0 usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
30000 usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
26000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-29000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-123000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52000 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
mhtx Non Cash Investment In Equity Shares Transferred To Pay Note Down
NonCashInvestmentInEquitySharesTransferredToPayNoteDown
0 usd
mhtx Non Cash Investment In Equity Shares Transferred To Pay Note Down
NonCashInvestmentInEquitySharesTransferredToPayNoteDown
30000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72955000 usd
CY2024Q2 mhtx Working Capital
WorkingCapital
-2371000 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
0 usd
mhtx Common Stock Owned Share
CommonStockOwnedShare
476662 shares
CY2024Q2 us-gaap Investments
Investments
27000 usd
CY2023Q4 us-gaap Investments
Investments
245000 usd
us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21155760 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26655760 shares
us-gaap Net Income Loss
NetIncomeLoss
-540000 usd
us-gaap Net Income Loss
NetIncomeLoss
-649000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q4 us-gaap Investments
Investments
245000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-188000 usd
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
30000 usd
CY2024Q2 us-gaap Investments
Investments
27000 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.04
mhtx Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term28 D
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm28D
P4Y29D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26500000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5500000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.10
mhtx Share Based Compensation Arrangement By Share Based Payment Award Options Expired Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber
5500000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21000000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.03
mhtx Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2
P4Y7M9D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
21000000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
26500000 shares
mhtx Royalty Percentage On Dental Products
RoyaltyPercentageOnDentalProducts
0.10 pure
mhtx Royalty Percentage On Other Licensed Products
RoyaltyPercentageOnOtherLicensedProducts
0.05 pure
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2180000 usd

Files In Submission

Name View Source Status
0001477932-24-005089-index-headers.html Edgar Link pending
0001477932-24-005089-index.html Edgar Link pending
0001477932-24-005089.txt Edgar Link pending
0001477932-24-005089-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mhtx-20240630.xsd Edgar Link pending
mhtx_10q.htm Edgar Link pending
mhtx_ex311.htm Edgar Link pending
mhtx_ex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
mhtx-20240630_def.xml Edgar Link unprocessable
mhtx-20240630_pre.xml Edgar Link unprocessable
mhtx-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mhtx-20240630_cal.xml Edgar Link unprocessable
mhtx_10q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending